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ARTICLE
Allosteric pyruvate kinase-based “logic gate”
synergistically senses energy and sugar levels in
Mycobacterium tuberculosis
Wenhe Zhong1,2, Liang Cui1, Boon Chong Goh1,2, Qixu Cai3, Peiying Ho1, Yok Hian Chionh 1,7, Meng Yuan4,8,
Abbas El Sahili2,5, Linda A. Fothergill-Gilmore4, Malcolm D. Walkinshaw 4, Julien Lescar2,5 & Peter C. Dedon1,6
Pyruvate kinase (PYK) is an essential glycolytic enzyme that controls glycolytic ﬂux and is
critical for ATP production in all organisms, with tight regulation by multiple metabolites. Yet
the allosteric mechanisms governing PYK activity in bacterial pathogens are poorly under-
stood. Here we report biochemical, structural and metabolomic evidence that Mycobacterium
tuberculosis (Mtb) PYK uses AMP and glucose-6-phosphate (G6P) as synergistic allosteric
activators that function as a molecular “OR logic gate” to tightly regulate energy and glucose
metabolism. G6P was found to bind to a previously unknown site adjacent to the canonical
site for AMP. Kinetic data and structural network analysis further show that AMP and G6P
work synergistically as allosteric activators. Importantly, metabolome proﬁling in the Mtb
surrogate, Mycobacterium bovis BCG, reveals signiﬁcant changes in AMP and G6P levels
during nutrient deprivation, which provides insights into how a PYK OR gate would function
during the stress of Mtb infection.
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Mycobacterium tuberculosis (Mtb) is among the deadliestinfectious diseases on a global scale, killing more thanone-million people annually1, with emerging anti-
microbial drug resistance posing serious challenges to existing
diagnosis and treatment programs1. Although generally con-
sidered aerobic, Mtb has successfully adapted to the hypoxic and
carbon-poor environment in human macrophages by evolving
ﬂexible carbon metabolism and co-catabolism to defend against
the stresses posed by the human immune system2–4. In particular,
increasing evidence suggests that the metabolic ﬂexibility of
central carbon metabolism (CCM: glycolysis, gluconeogenesis,
pentose phosphate pathway and TCA pathway) is critical in Mtb
physiology and pathogenicity5–7. This is illustrated by the rapid
regulation of glycolytic activity in response to changes in ATP
levels, which explains the enhanced efﬁcacy of drug combinations
that target the electron transport chain8. Here we describe a
unique feature of the Mtb glycolytic enzyme, pyruvate kinase
(PYK), which provides insights into its pivotal role in Mtb CCM9
and the metabolic ﬂexibility of Mtb.
PYK (EC 2.7.1.40) forms a tetramer (Fig. 1a) that catalyzes
transfer of phosphate from phosphoenolpyruvate (PEP) to ADP
to form pyruvate and ATP. Given its central role in controlling
glycolytic ﬂux and ATP generation, PYK has been exploited as a
drug target in bacterial pathogens10, parasites11 and cancer12, and
was recently identiﬁed as a potential target of the antimalarial
drug artemisinin13. The activity of most PYKs is tightly controlled
by physiological modulators, with the notable exception of the
constitutive activity of mammalian muscle isoenzyme M1.
However, in spite of many decades of study, the complex allos-
teric mechanisms governing PYK activity in different organisms
have eluded deﬁnition. For example, while fructose 2,6-bispho-
sphate (F26BP) allosterically activates trypanosome PYKs14, the
upstream glycolytic intermediate, fructose 1,6-bisphosphate
(F16BP), is the most widely recognised allosteric activator of
PYKs in many bacteria15, 16, in yeast17 and in mammals18. In
general, PYKs from higher organisms have a single essential
modulator, with the exception of F16BP and amino-acid regula-
tion of human M2PYK in cancer-cell proliferation19–21. This
stands in contrast to the many bacterial PYKs that use ‘non-
canonical’ effectors such as AMP and the sugar monophosphates
glucose 6-phosphate (G6P) and ribose 5-phosphate (R5P) for
allosteric regulation (Supplementary Table 1), including PYKs
from important human pathogens such as Mtb9, Streptococcus
mutans22, Staphylococcus aureus23 and Salmonella typhimur-
ium16 (a sequence alignment of selected bacterial PYKs is shown
in Supplementary Fig. 1 and pairwise identities in Supplementary
Table 2).
One of the reasons that the allosteric mechanisms regulating
bacterial PYKs have remained elusive for decades is the lack of
structural information about the binding of physiological effec-
tors to identify allosteric sites. Here we report biochemical,
structural and computational modelling studies of Mtb PYK that
reveal a ‘rock-shape-lock’ allosteric mechanism regulated by the
synergistically acting activators AMP and G6P. Stress-induced
metabolomic changes in the Mtb surrogate, Mycobacterium bovis
BCG, point to AMP and G6P as molecular input signals that
position MtbPYK as a unique molecular OR ‘logic gate’ to sense
changes in energy and sugar levels during Mtb infection.
Results
Effectors AMP and G6P activate MtbPYK synergistically. We
ﬁrst performed detailed kinetic studies of puriﬁed MtbPYK to
evaluate AMP and G6P as allosteric activators and to test whether
they share a single binding site (Table 1). MtbPYK puriﬁed from
an Escherichia coli expression system was more active than that
reported by Noy et al.9 under similar assay conditions, with a kcat
value of 183± 1 s−1 versus 63 s−1, respectively (Supplementary
Table 1), and it showed hyperbolic kinetics with respect to its
substrate ADP, with a Km value of 0.47± 0.02 mM. For the
substrate PEP, the enzyme displayed sigmoidal kinetics in the
absence of effector, with a S0.5 value of 0.41± 0.01 mM and a Hill
coefﬁcient (h) of 1.82± 0.05, indicating positive cooperativity.
The afﬁnity to substrate PEP was estimated by its S0.5 value in the
presence of saturating ADP. Therefore, both AMP and G6P
enhanced the afﬁnity of PEP by ~2-fold and decreased the
cooperativity with respect to PEP (h= ~1.2). Inhibition by the
product ATP (Supplementary Fig. 2) reduced PEP afﬁnity by 5-
fold (S0.5 = 2.20± 0.08 mM) and increased the cooperativity to
PEP (h = ~2.6). ATP inhibition was reversed by adding the
allosteric activators AMP and G6P.
The concentrations of AMP and G6P were then varied to
investigate their interplay in enzyme activation (Table 1). The
Ka0.5 value of AMP fell up to 3.2-fold (~64 to ~20 µM) as the
concentration of G6P was increased. In a similar manner, the
apparent afﬁnity of G6P increased up to 3.5-fold (~147 to ~42
µM) with increasing AMP. This positive cooperativity between
AMP and G6P suggests two distinct binding sites instead of
competitive binding to the same effector site. In addition, the
enzyme catalytic efﬁciency, which is estimated by kcat/S0.5 value
(Table 1), is also enhanced by the synergy of AMP and G6P. In
contrast to previous computational studies in which effectors
were docked at a single canonical allosteric site of bacterial
PYKs24, our kinetic results demonstrate that AMP and G6P act in
synergy to allosterically activate MtbPYK and suggest two
cooperative allosteric sites. The latter was borne out in structural
studies.
A rigid-body rocking motion in allosteric transition. More than
40 years ago, Waygood et al.25 demonstrated for the ﬁrst time
that AMP and G6P were the activators of PYK using the E. coli
enzyme as the model. However, AMP- or G6P-bound PYK
structures have been hitherto unavailable to elucidate the corre-
sponding effector sites and allosteric mechanisms. Here, we have
successfully determined a series of six high-resolution crystal
structures of PYK from M. tuberculosis in both inactive T-state
and active R-state, and with or without AMP and G6P (Table 2).
MtbPYK adopts a tetrameric architecture formed by identical
subunits with three domains (A, B and C domains) (Fig. 1a),
similar to typical PYK structures. The catalytic site is located in
the cleft between the A and B domains (lid domain), while the C
domain harbours a canonical AMP allosteric site. The allosteric
site binding for G6P (sugar monophosphate site) is adjacent to
the AMP site and lies between the A and C domains (Fig. 1b). It is
noteworthy that the amino-acid binding site of human M2PYK is
also formed by the A and C domains but is located on the
opposite pole of the molecule relative to the canonical allosteric
site (Fig. 1b).
The allosteric mechanism was analysed at the level of
quaternary protein structure by superposition of the inactive T-
state tetramer structure (PDB: 5WRP) onto the fully ligated R-
state tetramer structure (MtbPYK-OX/AMP/G6P; PDB: 5WSB)
excluding the mobile B domains. This gave an RMS ﬁt of 3.2 Å for
all C-α atoms. The superposition analysis suggests that each
subunit of the MtbPYK tetramer simultaneously undergoes a 9°
AC-core (A and C domains) rigid-body rotation concomitant
with the T- to R-state transition (Fig. 2a, b; Supplementary
Table 3), which is consistent with the ‘rocking motion’
mechanism observed in trypanosomatid PYKs14, 26, 27 and
human M2PYK19. We have also compared the rigid-body
rotation angles from T-state to different ligated R states of the
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-02086-y
2 NATURE COMMUNICATIONS | 8:  1986 |DOI: 10.1038/s41467-017-02086-y |www.nature.com/naturecommunications
MtbPYK tetramer (Supplementary Table 3), and observed similar
motion angles (<1° variation). Our results provide the detailed
structural evidence that bacterial PYKs possess a concerted
‘rocking motion’ allosteric mechanism (Supplementary Movie 1),
despite having a distinct repertoire of allosteric effectors.
The interplay between AMP and C-terminal tail loops. We next
explored the determinants of this concerted rigid-body rotations
of all four chains during the allosteric interconversion of T- and
R-states in the MtbPYK tetramer (Fig. 2a, b). Unlike trypanoso-
matid PYKs that use additional salt bridges across the C–C
interface to stabilise the R-state tetramer structure14, 26, 27, the
motions of the AC-cores in MtbPYK require the disruption of
C–C interface interactions between the AMP loop and the
C-terminal tail loop (Thr455…Asp470), as well as the hydrogen
bonds (H-bonds) formed between the two adjacent
Cα4 structures (Thr422…Asp423) (Fig. 2c, d). The electron
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density of the AMP loop is poorly identiﬁed in the R-state
MtbPYK-OX structure (PDB: 5WS8) indicating high ﬂexibility in
the absence of effector binding.
The relocation of the AMP loop leaves a free space at the C–C
interface and thus allows the reorganisation of the C-terminal tail
loop (Fig. 2c). This tail loop ﬂips ~180° to approach the C–C
interface and forms H-bonds with the Cβ4 strand from the same
protein chain (Asp471…His463/His465) while the hydrophobic
residue Val472 (the C-terminal portion of the tail loop) forms a
hydrophobic interaction with the side-chain of Ile426 in helix
Cα4 (Fig. 2d). This ‘in-and-out’ interplay between the AMP loop
and the C-terminal tail loop, in response to the transition between
T- and R-states, favours the formation of the R conformation by
abolishing interface H-bonds and generating new interactions
within each protomer (Supplementary Movie 2). The loss of
interface interactions is also in agreement with the reduction in
the C–C interface area in the R-state (Supplementary Table 4).
The thermal stability of MtbPYK in all possible ligated states
was determined in the presence of a wide variety of ligands by
performing ﬂuorescence-based thermal shift assays (Supplemen-
tary Fig. 3). When one or more allosteric ligands were mixed with
the enzyme in the presence of substrate PEP or oxalate, the
thermal vibration decreased (ΔTm = 1–10 °C), suggesting that the
stability of the R conformation is enhanced by a network of
interactions between allosteric ligands and each protein subunit,
which overcomes the reduction in C–C interface interactions.
Kinetic evidence of enzyme activation by AMP and G6P
correlates well with the enhanced rigidity of the R-state PYK in
the presence of AMP and G6P. The physical AMP and G6P
binding sites were established next, with the discovery of the
G6P-binding site.
AMP binds at the canonical allosteric site. While AMP binds
tightly at the canonical allosteric site of PYK (Fig. 3) that recruits
bisphosphate effectors such as F16BP17, 18 and F26BP14 in many
organisms, the MtbPYK AMP binding site has several unique
features. In MtbPYK, the AMP phospho group is H-bonded to
residues Thr374, Gln375, Ser376, Thr379 and AMP-loop residue
Gly457, and forms a salt bridge with the side-chain of Arg351 in
helix Cα1. By comparison with the AMP-free T-state structure
(PDB: 5WRP), the effector loop (residues 451–458) moves further
from the dimer–dimer (C–C) interface to wrap around AMP and
form H-bonds with it. The adenine-binding site for AMP is
relatively hydrophobic and is composed of residues Phe373,
Trp398 and Met425. These residues form stacking interactions
with the adenine ring of AMP (Supplementary Fig. 4). Interest-
ingly, the binding of Trp398 to AMP requires reorientation of the
side chain of this residue to close up the AMP pocket. The fact
that Trp398 is not highly conserved in other AMP-activated
PYKs (Supplementary Fig. 1) suggests a unique regulatory
function in MtbPYK. Hydrophobic residues Phe373 and Met425
are relatively conserved among PYKs that use AMP as activator.
Residue Met425 in helix Cα4 is normally replaced by arginine in
F16BP- or F26BP-activated PYKs14, 17, 18 (Supplementary
Fig. 5a), whereby a positively charged side chain is essential to
form a salt bridge with the negatively-charged 1′- or 2′-phospho
group to hold the effector in place. Moreover, Gln375 in MtbPYK
is substituted by a positively charged lysine residue in human
M2PYK which interacts with the 1′-phospho group of F16BP via
a salt bridge18 (Supplementary Fig. 5a). Therefore, the hydro-
phobicity of the adenine-binding site in the AMP pocket is strictly
required for recognition. By contrast, in F16BP- or F26BP-
activated PYKs, the effector site needs to provide more positive
charges (Arg, Lys substitutions) to recognise and lock both
negatively charged phospho groups in place.
G6P binds at an allosteric site adjacent to canonical site. The
kinetics-based prediction of a unique G6P-binding site was borne
out in the structural analyses. The MtbPYK structures in complex
with G6P reveal an allosteric site that is distinct from the cano-
nical AMP-binding allosteric site (Fig. 3). The G6P site is located
at the boundary between the A and C domains (Fig. 1), and is
composed of helices Aα6, Cα1, Cα2 and the G6P-loop (Fig. 3).
Two positively-charged residues Arg382 and Arg385 in Cα2 lock
the G6P phospho group in place via salt bridges together with
three H-bonds provided by three residues in the G6P-loop
(His345, Arg348, Thr349). Interestingly, the side-chain of His345
in the G6P loop adopts multiple positions within a tetramer in the
absence of G6P binding, but is locked in one position by
H-bonding to G6P. The sugar group of G6P makes a H-bond
with the main-chain of Asn268 in Aα6. Water molecules further
stabilise G6P. In contrast, the corresponding site in non-G6P-
regulated PYKs (i.e., trypanosome PYK, human M2PYK) has
more negatively-charged residues that could prevent G6P binding
(Supplementary Fig. 5b).
Structurally, Cα1 bridges the AMP and G6P sites, where
Arg351 in Cα1 forms an ionic pair with AMP and Thr349 (next
to Cα1) interacts with the G6P phospho group by H-bonding.
The presence of this prominent structure network of AMP…
Cα1…G6P correlates well with the kinetic synergy between AMP
and G6P. These results suggest the existence of two physical
allosteric pathways linking the AMP and G6P binding sites with
the active site ~40 Å away, which was established next.
Dual allosteric pathways with synergistic cooperation. To
explore the physical basis for this dual allostery, we performed a
molecular dynamics (MD) simulation on the tetramer ofMtbPYK
with bound OX/AMP/G6P in order to identify potential allosteric
pathways between the catalytic site (OX site) and the two allos-
teric sites (AMP and G6P sites). The allosteric pathways between
Fig. 1 Structure of MtbPYK and overview of three allosteric sites of PYK. a Crystal structure of the MtbPYK-OX/AMP/G6P complex (PDB ID 5WSB) in the
synergistically activated R-state. Two orthogonal views of MtbPYK-OX/AMP/G6P show the tetramer architecture, domain boundaries, active site and
synergistic effector sites. The A–A (large) and C–C (small) interfaces between subunits are shown as dashed lines. Each subunit comprises three domains,
and one subunit (chain A) is coloured to show the domains: A-domain in green (residues 1–70, 168–336), B-domain in yellow (residues 71–167), C-domain
in cyan (residues 337–472). The N terminus and C terminus of this subunit are indicated. Polypeptide chains are shown as cartoons, while metals and
ligands are represented by spheres. Mg2+ and K+ located at the active site (brown box) are coloured in green and purple, respectively. The oxalate
molecule (OX) at the active site is associated with the Mg2+. The canonical allosteric site (AMP-bound) is indicated by the purple box, while the newly
discovered G6P-binding site (synergistically coordinating with the AMP-binding site) is shown by the magenta box. The AMP-binding loop (AMP loop) and
G6P-binding loop (G6P loop) are coloured black. The C-terminal loop (tail loop) which undergoes a conformational change in the transition of inactive- and
active states is indicated. b A surface representation of the PYK monomer (A-, B- and C-domains) highlighting three allosteric effector sites: canonical
allosteric site that binds AMP, F26BP or F16BP; amino-acid site found in mammalian M1/M2PYK that binds amino acids as a nutrient sensor; sugar
monophosphate site that binds G6P in M. tuberculosis synergistically coordinating with the canonical site, and probably binds R5P or G3P in some
organisms. The A-, B- and C domains are shown in green, yellow and cyan, respectively. Effector-site ligands are shown as spheres
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oxalate and AMP/G6P were then extracted from the MD simu-
lation using the Weighted Implementation of Suboptimal Path-
ways (WISP)28. Dominant allosteric pathways connecting oxalate
and AMP (OX-AMP), as well as connecting oxalate and G6P
(OX-G6P), are shown in Fig. 4a, b. An allosteric pathway was
considered dominant when it consisted of a set of residues with
high frequency of occurrence in the histogram shown in Fig. 4c.
The two allosteric pathways propagate through three identical
residues en route to the catalytic site, namely Ala237, Ala217 and
Lys218, which suggests that synergistic cooperation exists, per-
haps at the level of individual MtbPYK monomers. Further
community analysis revealed that AMP and G6P-binding sites
belong to the same group of highly correlated residues (Supple-
mentary Fig. 9), suggesting binding of either activator could
allosterically regulate the catalytic binding site. This was explored
next.
Table 2 Data collection and reﬁnement statistics
T-state MtbPYK MtbPYK-OX MtbPYK-OX/ATP/
AMP
MtbPYK-OX/G6P MtbPYK-OX/AMP/
G6P
MtbPYK- OX/AMP/
G6P (soak)
PDB ID 5WRP 5WS8 5WS9 5WSA 5WSB 5WSC
Data collection
Space group P212121 P31 P31 P31 P31 P31
Cell dimensions
a, b, c (Å) 90.76,129.48,243.98 127.01,127.01,144.65 127.19,127.19,144.92 125.42,125.42,144.19 125.63,125.63,144.51 124.37,124.37,144.19
α, β, γ (°) 90.00,90.00,90.00 90.00,90.00,120.00 90.00,90.00,120.00 90.00,90.00,120.00 90.00,90.00,120.00 90.00,90.00,120.00
Solvent content (%)
65 63 63 62 62 61
Resolution (Å) 88.79–2.85 63.51–2.62 60.54–1.90 62.71–2.85 62.82–2.25 53.85–2.40
No. of reﬂections 271,505 (15,837) 432,224 (25,144) 1,001,199 (43,594) 333,176 (25,316) 616,913 (15,502) 541,318 (24,538)
No. of unique
reﬂections
67,441 (4498) 78,513 (4558) 206,700 (10,249) 59,240 (4587) 120,301 (5497) 97,539 (4826)
Wilson
B-factor (Å2)
55.070 50.351 23.261 37.737 31.826 24.399
Rmerge (%) 11.4 (92.7) 9.4 (75.6) 7.1 (44.6) 10.3 (45.5) 10.0 (89.9) 17.4 (86.8)
I/σI 7.9 (1.1) 10.6 (2.2) 12.0 (3.0) 13.7 (3.3) 9.9 (1.4) 8.3 (1.6)
Completeness (%) 99.4 (99.9) 100.0 (100.0) 100.0 (100.0) 100.0 (100.0) 99.3 (92.1) 100.0 (99.9)
Multiplicity 4.0 (3.5) 5.5 (5.5) 4.8 (4.3) 5.6 (5.5) 5.1 (2.8) 5.5 (5.1)
Reﬁnement
Monomers in ASU 4 4 4 4 4 4
No. of reﬂections 63,878 74,461 195,933 56,202 114,312 92,706
Rwork/Rfree 0.2056/0.2330 0.1734/0.2178 0.1968/0.2229 0.1509/0.1953 0.1870/0.2278 0.1793/0.2270
No. of non-H atoms
Protein 13549 14044 14211 14172 14172 14172
Water 234 494 1440 172 410 335
Ligands 20 28 269 112 195 195
Average B-factor (Å2)
Protein 76.0 70.2 36.3 43.6 37.4 28.2
Water 55.8 57.7 43.4 24.3 27.2 22.1
Ligands 76.8 65.9 47.4 32.8 31.1 23.4
AMP/G6P N.A. N.A. 30.0 33.1 30.9 23.6
RMS deviations
Bond lengths (Å) 0.0123 0.0117 0.0121 0.0143 0.0119 0.0140
Bond angles (°) 1.1760 1.1809 1.2636 1.3289 1.3243 1.5284
Ramachandran plots
Favoured (%) 97.1 96.7 98.3 97.2 97.3 97.8
Allowed (%) 99.8 99.8 99.6 99.8 99.6 99.6
Number of outliers 4 4 8 4 8 8
Values in parentheses are for the highest resolution shell
N.A. not applicable
Table 1 Kinetic properties of MtbPYK
Ligand Kinetic parameter Modulators
None +AMPa +G6Pa +AMP/G6Pa +ATPa +ATP/AMP/G6Pa
PEP S0.5 (mM) 0.41± 0.01 0.25± 0.01 0.18± 0.01 0.18± 0.01 2.20± 0.08 0.37± 0.01
h 1.82± 0.05 1.21± 0.04 1.24± 0.07 1.23± 0.03 2.63± 0.21 1.15± 0.03
kcat (s−1) 183± 1.2 194.8± 2.1 172.7± 2.8 188.8± 1.4 101± 2.7 136± 1.3
kcat/S0.5 446 780 960 1049 46 367
ADP Km (mM) 0.47± 0.02 N.A.
None + AMP +G6P
12.5 µM 25 µM 25 µM 50 µM
AMP Ka0.5 (µM) 63.5± 2.9 N.A. N.A. 35.7± 0.9 20.3± 1.4
G6P Ka0.5 (µM) 147± 5.8 55.4± 3.1 42.2± 3.4 N.A. N.A.
kcat/S0.5 values in s−1 mM−1
h Hill coefﬁcient, N.A. not applicable
aThe concentrations of modulators in the kinetic study of PEP are: AMP—1 mM, G6P—1 mM, ATP—2mM
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A synergistic allostery beyond rock-and-lock. Studies of PYKs
from trypanosomatids14 and humans19 have established an
allosteric ‘rock-and-lock’ regulation mechanism involving rigid-
body rotations of each subunit in the tetramer. We have
demonstrated this in MtbPYK (Fig. 2). However, the conforma-
tional ﬂexibility within each subunit of the tetramer has not yet
been reported, except for the ﬂexible effector loop and the mobile
B domain27 (Supplementary Fig. 6; Supplementary Table 5). To
study this type of structural plasticity and to probe the mobile
secondary structural elements (α helix, β strand, loops), we
superposed monomers (instead of tetramers) of all available R-
state MtbPYK structures onto the T-state monomer structure.
The mobile B domain and AMP loop were excluded from the
superposition. The distances between Cα-carbons following
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superposition ranged from 0.7 to 1.1 Å (Supplementary Table 3),
which indicates only a subtle change in structure. We then further
analysed the superposition data by plotting a heat-map using the
Cα distance of each pair of superposed atoms (Supplementary
Fig. 7). The heat-map clearly reveals correlated local structural
rearrangements (shown in red) in response to the concerted rigid-
body motion and the AMP/G6P synergistic binding. This indi-
cates the ‘plastic’ nature of a MtbPYK monomer, as illustrated in
Fig. 5 and Supplementary Movie 3.
AMP/G6P kinetic synergy results from a synergistic allostery.
A more granular analysis of the allosteric site reshaping upon
AMP and G6P binding revealed a unique mechanism underlying
the AMP/G6P kinetic synergy. Cα1 and Cα4 are essential α
helices at the two allosteric sites of MtbPYK that regulate the
binding of G6P and AMP, respectively (Fig. 3). Both exhibit
obvious movements during the T- and R-state transition (Fig. 5;
Supplementary Fig. 7). This structural plasticity of allosteric sites
in response to effector binding has not been reported in any other
PYK. We then further analysed the movements of superposed
structures and found that Cα1 and Cα4 both rotated and shifted
by ~6° from the T-state (yellow) to the fully ligated R-state (cyan)
(Fig. 5). In contrast, other non-fully ligated MtbPYK R-state
structures exhibit less obvious but similar Cα1/Cα4 motion
during the T- and R-state interconversion. Brieﬂy, as shown in
Fig. 5, only a subtle movement of Cα1 is observed between the T-
(yellow) and oxalate-bound R-state (MtbPYK-OX; orange), with
Cα4 remaining static. AMP binding (purple) triggers nearly
maximum Cα4 movement (~6°) but modest Cα1 movement. By
contrast, G6P binding (magenta) causes Cα1 to shift nearly
maximally (~6°), but with only a subtle movement of Cα4. To
further conﬁrm the structural plasticity of MtbPYK allosteric
sites, we soaked AMP and G6P into MtbPYK-OX crystals
resulting in nearly identical allosteric sites (Cα RMS ﬁt: 0.17 Å)
compared with that of the fully ligated R-state structure deter-
mined from the crystal using a co-crystallization method. Both
fully ligated R-state structures, obtained from distinct crystal-
lization methods, display the same degree of Cα1/Cα4 movement
(~6°) during the T- and R-state transition, further demonstrating
the dramatic plasticity of the allosteric-site structures regulated by
effectors.
Thus, the displacements of helices Cα1 and Cα4 resulting in
allosteric-site reshaping are not substantially regulated by rigid-
body rotation, but instead are correlated with the presence of
AMP and G6P. This unique ‘synergistic allostery’ suggests that
the binding of either activator is able to initiate the movements of
both Cα1 and Cα4 to a certain extent and consequently reshape
the allosteric sites to favour binding of the other activator. The
synergy of AMP and G6P shown in structural rearrangements
agrees with the ﬁndings in enzyme kinetics where the presence of
one activator promotes the activation efﬁciency of the other
(Table 1). Furthermore, the binding of activators shows a
remarkable increase in the thermal stability of R-state MtbPYK
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with a ΔTm value of 4–9 °C (Fig. 6d; Supplementary Fig. 3),
suggesting that allosteric-site reshaping enhances the stability of
the R-state conformation.
It is noteworthy that the helix bundle Aα6′–Aα6 that is located
at the A–A interface exhibits a ~6° rotation around the pivot near
Asn268 during T- and R-state inter-conversion. No further
movement is observed between R-state structures of different
ligated states, suggesting that the conformational rearrangement
of Aα6′–Aα6 only correlates with the concerted rocking motions,
and is required in any R-state structure. The movement of Aα6′-
Aα6 plays a role in forming an ‘active’ catalytic site for the
binding of substrate and its cofactor (Fig. 5), in agreement with
our previous ﬁndings in Trypanosoma brucei PYK, where we
showed the reorientations of side chains of active-site residues for
substrate binding27. In addition, another pair of A–A interface
helices Aα7′ and Aα7, which display modest movement shown in
the heat-map, form a H-bond across the A–A interface with the
adjacent helix pair Aα6′ and Aα6 via the side-chain rotation of
Arg290 (Supplementary Fig. 8). One consequence of the T and R
transition is therefore to reorganise the positions of Aα6′–Aα6
and Aα7′–Aα7 to transform the catalytic site between its ‘active’
and ‘inactive’ conformations.
A molecular logic gate senses metabolic changes in vivo. The
preceding biochemical and structural results are all consistent
with the idea that MtbPYK functions as an ‘OR logic gate’ to
tightly regulate metabolism based on integration of AMP and
G6P levels during the large metabolic shifts that occur during the
stress of infection. The ‘rock-and-lock’ model for trypanosome
PYK allostery26 and the ‘dock-rock-lock’ model for human
M2PYK allostery19 are based largely on structural evidence. Until
now, a lack of bacterial PYK structures with native effectors
bound precluded any comparisons between prokaryotic and
eukaryotic enzymes. The MtbPYK structures presented here
reveal atomic-level details of a unique AMP/G6P synergism
controlling PYK allostery. We propose a three-step ‘rock-shape-
lock’ model to describe the synergistic allostery of MtbPYK: (1)
Subunits of the MtbPYK tetramer rock 9° simultaneously from
the T-state to the R-state (Supplementary Fig. 8a, b) in response
to substrate binding, movements that are coupled with interface-
loop interplay and catalytic-site formation via the movement of
helices Aα6′ and Aα6. (2) AMP and G6P binding reshapes the
allosteric sites by local conformational changes (Supplementary
Fig. 8c–e), with the two allosteric pathways working indepen-
dently or in positive cooperativity. (3) A network of interactions
within and between allosteric sites is then established, which
‘double locks’ the PYK tetramer in the most catalytically efﬁcient
active state termed the ‘synergistically activated R-state’ (Sup-
plementary Fig. 8c).
This dynamic model is consistent with the idea of an OR logic
gate that enables MtbPYK to sense changes in both AMP and
G6P levels and appropriately modulate enzyme activity during
stress-induced metabolic shifts. This logic gate regulatory activity
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of PYK can be understood in the context of the metabolic shift
that occurs during mycobacterial nutrient deprivation mimicking
the tubercular granuloma. M. bovis BCG is a well-established
experimental surrogate of Mtb for studying metabolism. In
particular, the PYK protein sequence is identical for the two. Here
we used LC-MS to quantify changes in the level of glycolytic
intermediates in M. bovis BCG subjected to nutrient deprivation.
As shown in Fig. 6a, starvation caused signiﬁcant reductions (up
to 30-fold) of G6P compared with logarithmic growth, which
should lead to downregulation of PYK. In contrast, AMP levels
increased (up to 4-fold) at 4 and 10 days of starvation (S4 and S10
in Fig. 6). This should upregulate PYK activity early in nutrient
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deprivation. Additionally, the PYK substrates ADP and PEP
accumulate at S4 and S10, where PEP is a toxic glycolytic
intermediate that inhibits isocitrate dehydrogenase in the TCA
cycle9. These shifts in PYK activity as a function of AMP and G6P
levels thus satisfy the criteria for an OR logic gate (inset table in
Fig. 6b) that enables PYK to sense the stress-induced reduction of
G6P and increase of AMP (Fig. 6a), and to continually keep PYK
primed to facilitate potential carbon co-catabolism and prevent
further accumulation of toxic metabolites during the stress-
induced metabolic shifts (output in Fig. 6b).
Discussion
This ﬂexibility of CCM is essential for mycobacterial physiology
and pathogenicity, particularly under the stresses of infection2.
Allosteric mechanisms of key CCM enzymes enable bacteria to
efﬁciently sense the changes in metabolite levels and react
immediately by allosterically regulating mechanisms to maintain
homoeostasis and defence against environmental threats5. The
results from our biochemical, structural and metabolic studies
uncover a unique ‘rock-shape-lock’ allostery, which endows PYK
as a molecular OR logic gate to simultaneously sense the changes
of AMP and G6P levels in a synergistic manner (Fig. 6a, b). This
OR gate uses AMP (the low-energy-state signal) and G6P
(essential for M. tuberculosis pathogenesis29, 30) as molecular
inputs to promote PYK activity (output), where either input at a
certain concentration is able to fully activate the enzyme activity
for the needs of the bacterium (Fig. 6c). Our ﬁndings also shed
light on the importance of enzyme evolution providing M.
tuberculosis with metabolic ﬂexibility and the ability to adapt to
challenging environmental changes. The conservation of key
residues in AMP and G6P binding suggests that the above
allosteric model is likely to apply to other bacterial PYKs.
Importantly, our results provide both structural foundation and
allosteric mechanism for designing MtbPYK inhibitors that could
potentially provide a fast-killing therapy in combination with
respiratory ATPase inhibitors like bedaquiline8 to completely
block ATP production.
Methods
Cloning and protein production. A series of gene codon-optimisation procedures
from Bio Basic Inc. were applied to improve the efﬁciency of soluble expression of
MtbPYK in E. coli (Supplementary Table 6). The codon-optimised gene was syn-
thesised and cloned into a pYUB28b-TEV vector by Bio Basic Inc. The vector
pYUB28b-TEV is modiﬁed from pYUB28b (Addgene #37277) that was provided
by Dr. Ghader Bashiri from The University of Auckland. The veriﬁed construct
(pYUB28b-TEV_MtbPYK) allows the expression of N-terminal 6xhistidine-tagged
MtbPYK with subsequent tag removal by TEV protease digestion.
MtbPYK was overexpressed in E. coli BL21(DE3) cells (Novagen, Merck
Millipore) and puriﬁed as described previously27 with some modiﬁcations. Brieﬂy,
10 ml of overnight culture was inoculated in 500 ml of 2xTY medium with 50 μg ml
−1 hygromycin B and grown to OD600 = 0.6–0.8 at 37 °C. MtbPYK protein
overexpression was induced by 0.5 mM IPTG after a 30 min incubation at 4 °C.
The cells were further cultured for another 24 h at 16 °C before harvesting.
Cell pellets were lysed in ice-cold buffer (50 mM triethanolamine-HCl (TEA)
pH 7.2, 300 mM KCl, 20 mM imidazole, 10% glycerol) using a Constant Systems
Cell Disruptor (Panda) (set to 850 bar). The soluble fraction was obtained by
centrifugation at 39,191 × g for 45 min. The supernatant was ﬁltered through a
0.22 μm syringe ﬁlter then applied onto an ÄKTA system ﬁtted with 1 ml HisTrap
HP IMAC column (GE Healthcare) (prepacked with Ni Sepharose). The column
was maintained at a constant ﬂow rate of 1.0 ml min−1 throughout the whole-
puriﬁcation process. Following loading of the clariﬁed lysate, the column was
washed with 20 column volumes of cell-lysis buffer. The target enzyme MtbPYK
was eluted from the column by applying 100% elution buffer (50 mM TEA pH 7.2,
300 mM KCl, 500 mM imidazole, 10% glycerol) and digested with TEV protease at
4 °C for 12 h to remove the 6xhistidine tag. The digested sample was dialysed
against lysis buffer and loaded onto a HisTrap HP IMAC column (pre-equilibrated
in cell-lysis buffer). The untagged enzyme MtbPYK was collected from the ﬂow-
through fractions and concentrated to 5 ml using a Vivaspin column (GE
Healthcare, 100 kDa cutoff).
Concentrated proteins were then loaded onto a HiLoad 16/600 Superdex 200
prep grade gel-ﬁltration column with a ﬂow rate of 1.0 ml min−1 in a buffer
containing 20 mM TEA pH 7.2, 50 mM KCl, 10 mMMgCl2, 20% glycerol.MtbPYK
proteins eluted in a peak at ~63 ml and were further analysed on SDS–PAGE. Pure
proteins (>95% purity) were concentrated to at least 20 mgml−1 and were stored at
−80 °C. The protein concentration was determined by measuring the absorbance at
280 nm with an extinction coefﬁcient for MtbPYK of 25,440M−1 cm−1.
Enzyme activity assay and kinetic studies. The activity and kinetics of MtbPYK
were determined as described for T. brucei PYK previously27 with some mod-
iﬁcations. Brieﬂy, PYK activity was measured by following the decrease in NADH
absorbance at 340 nm using a BioTek Synergy 4 microplate reader and the data
were analysed by the software Graphpad Prism 7. The assay was performed at 25 °
C in 100 μl reaction mixtures consisting of 1x assay buffer (50 mM TEA pH 7.2,
100 mM KCl, 10 mM MgCl2), 0.5 mM NADH, 3.2 U LDH and 1 μg ml−1 MtbPYK.
The speciﬁc activity of MtbPYK was calculated from the corresponding kinetic
curve. One activity unit is the reaction of 1 μmol substrate per minute under the
condition used in this assay. The turnover value (kcat) of MtbPYK was calculated
from the speciﬁc activity divided by the subunit molar mass of 50,950.4 g mol−1.
Enzyme kinetics with respect to ADP were studied with saturated PEP (8 mM)
and at variable concentrations of ADP (from 0 to 4 mM). Enzyme kinetics with
respect to PEP were studied with saturated ADP (4 mM) and at variable
concentrations of PEP (from 0 to 8 mM) in the presence or absence of 1 mM
activator AMP or G6P, or 2 mM inhibitor ATP. The combinations of effectors were
also studied: 1 mM AMP plus 1 mM G6P with or without 2 mM ATP. The
hyperbolic kinetics with respect to ADP and sigmoidal kinetics with respect to PEP
were analysed using Graphpad Prism 7, respectively.
Enzyme kinetics with respect to the synergistic activators AMP and G6P were
studied at 4 mM ADP, 0.2 mM PEP and variable concentrations of AMP and G6P.
The synergistic activation was studied by adding G6P or AMP in AMP titration or
G6P titration. The synergistic activation by AMP was studied in the presence of
G6P (25 or 50 µM) and variable concentrations of AMP (from 0 to 3.2 mM). The
synergistic activation by G6P was similarly studied in the presence of AMP (12.5 or
25 µM) and variable concentrations of G6P (from 0 to 3.2 mM). The enzyme
kinetics with respect to allosteric effectors were analysed with Graphpad Prism 7
using an allosteric sigmoidal model. All kinetic results are summarised in Table 1.
A 3D bar illustration was plotted by MATLAB showing the relation of effector
concentrations and MtbPYK enzyme activity, where x/y-axis represents the effector
concentration and the height (z-axis) is the percentage (%) of enzyme’s maximum
rate (Vmax).
Fig. 6 Allosteric PYK-based molecular OR logic gate synergistically regulates energy and carbon metabolism in mycobacteria. Histograms of metabolic
changes at S4, S10, S22 and R6 against Log in nutrient-starvation model; abundance data were normalised to protein concentration and represent mean±
SD, n= 4; signiﬁcance is indicated as *p< 0.05, **p< 0.01, ***p< 0.001 by one-way ANOVA with Dunnett post test versus Log. a Schematic illustration of
glycolysis pathway and metabolic changes in M. bovis BCG during nutrient starvation. The allosteric activator of MtbPYK, glucose-6-P (G6P), is shown in
magenta, while PYK substrates (ADP and PEP) and products (ATP and pyruvate) are coloured in red. b A schematic representation of the molecular OR
gate. The metabolite G6P (magenta square) and the low-energy-state signal AMP (purple rectangle) are two molecular inputs into the gate which is
composed of inactive MtbPYK and its substrates (red trapezoid). The enzyme MtbPYK is activated (output) by the binding of either molecule input or both
molecules cooperatively at certain concentrations. The sensitivity to one input molecule is increased as the concentration of the other input molecule
increases. The MtbPYK tetramers in inactive T-state, AMP-activated R-state, G6P-activated R-state and AMP/G6P-activated R-state are all shown in
schematic representations. Domains are highlighted in one subunit: A domain in green, B domain in grey, C domain in blue. Secondary structures and
residues, that undergoes signiﬁcant movements from T-state to activated R-state, are shown as cartons and sticks. AMP loops are indicated as red lines. A
logic gate table is also shown on top. High= high concentration; Low= low concentration. c A three-dimensional (3D) graph shows the relation of activator
concentrations and MtbPYK activity in vitro. ‘%Vmax’ is expressed as the percentage of maximum velocity in the presence of saturating activators. The
activities were measured in vitro using puriﬁed MtbPYK in the presence of 4 mM ADP and 0.2 mM PEP. d Thermal shift assay results for ﬁve MtbPYK
complexes. All data are mean± SEM for two independent experiments done in duplicate
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Thermal shift assay. The thermal stability analysis of MtbPYK was determined as
described for T. brucei PYK previously27. Brieﬂy, the assay was performed in a 96-
well PCR plate (Bio-Rad) with 50 μl per reaction containing 5× SYPRO Orange dye
(Invitrogen), 4 μM MtbPYK enzyme and 10 mM of the test ligand(s) (PEP, oxalate,
pyruvate, ATP, AMP, G6P, F16BP, R5P, PO4). The assay buffer (50 mM TEA pH
7.2, 100 mM KCl, 10 mM MgCl2) was added instead of the test ligand as a negative
control. To start the experiment, the temperature was increased from 25 to 95 °C in
an i-Cycler iQ5 real-time PCR system (Bio-Rad). The thermal stability curve was
analysed using the Bio-Rad iQ5 software, then the temperature midpoint Tm for
the protein-unfolding transition was calculated.
Crystallization and data collection. The crystallisation experiments were per-
formed by the vapour-diffusion method using the hanging-drop technique at
4 °C. The drops were equilibrated against a reservoir ﬁlled with 1 ml well solution.
To crystallise MtbPYK in the inactive state (T-state), drops were formed by mixing
1.5 μl well solution with 1.0 μl protein solution (20 mgml−1). To co-crystallise the
enzyme with the PEP analogue oxalate (OX), product ATP or synergistic activators
G6P and AMP, 1.0 μl protein solution was mixed with 0.5 μl ligand solution (20
mM) and incubated at room temperature for 1–2 min. Then 1.5 μl well solution
was added to the mixture for crystallisation. Oxalate is a structural analogue of the
enolate form of pyruvate and has been generally used in crystallisation conditions
to stabilise PYK in the active R-state26, 27. The well solution consisted of 6–20%
PEG 8000, 10-20% glycerol, 50 mM TEA buffer pH 7.2, 100 mM KCl, 50 mM
MgCl2. Crystals of T-state MtbPYK, R-states MtbPYK-OX, MtbPYK-OX/ATP/
AMP and MtbPYK-OX/AMP/G6P were grown in conditions consisting of 11–16%
PEG 8000 plus 10–20% glycerol. Although ATP was also added to the crystal-
lisation conditions of the crystals MtbPYK-OX and MtbPYK-OX/AMP/G6P,
electron density of ATP was not discovered in either structure. Crystals of
MtbPYK-OX/G6P and MtbPYK-OX/AMP/G6P (different from the co-crystallised
one) were obtained by soaking MtbPYK-OX crystals with 5 mM G6P and 5mM
AMP/G6P mixture, respectively. The soaking solution contained 5 mM for each
ligand, 20% PEG 8000 and 20% glycerol.
X-ray intensity data for crystals of T-state MtbPYK and MtbPYK-OX/ATP/
AMP were collected at the Swiss Light source (SLS, Switzerland) while the intensity
data for crystals MtbPYK-OX, MtbPYK-OX/G6P, MtbPYK-OX/AMP/G6P and
MtbPYK-OX/AMP/G6P (soak) were collected at the Australian Synchrotron
(Australia). Each data set was from a single crystal ﬂash-cooled in liquid nitrogen at
100 K. Data were then processed with MOSFLM31 and scaled with AIMLESS32, 33.
The data-collection and processing statistics are summarised in Table 2.
Structure determination. The T-state MtbPYK structure was solved by molecular
replacement using the program Phaser34. The initial search model (MtbPYK
monomer) for the molecular-replacement experiment was obtained from the
I-TASSER server35. The structure was manually adjusted using Coot36 followed by
several cycles of restrained reﬁnement in REFMAC37. Where appropriate, water
molecules and ligands were added to the structure and TLS reﬁnement was applied
at later stage of reﬁnement. The mobile B-domain of chain C has poor density that
could not be improved after reﬁnement. Thus, this B-domain (residues 72–164)
was deleted from the ﬁnal reﬁned structure.
The diffraction data sets of the R-state MtbPYK structures [MtbPYK-OX,
MtbPYK-OX/ATP/AMP, MtbPYK-OX/G6P, MtbPYK-OX/AMP/G6P and
MtbPYK-OX/AMP/G6P (soak)] were scaled to the space group of P6422 with
reasonable statistics assessed by the program AIMLESS32, 33. The reﬁned structure
of the T-state MtbPYK monomer was used as the search model for molecular
replacement by Phaser34. After reﬁnement using REFMAC37 and manual model
building in Coot36, the R/Rfree remained high (both values >0.40 for data sets at
1.9–2.8 Å resolution). The L-test results indicated merohedral twinning had
occurred in data sets, although there is no twin law in the space group of P6422.
The data sets were then scaled to all possible space groups in lower symmetry with
possible twin laws. The results of molecular replacement and reﬁnement indicate
the data sets scaled in P31 have the most reasonable R/Rfree values (0.15–0.20) and
density qualities. The solved structures determined in space group P31 were further
reﬁned by following the procedures used for the T-state structure reﬁnement.
The quality of the structures was assessed using the MOLPROBITY server38,
and the ﬁgures were generated using PyMOL39. The data processing and
reﬁnement statistics are summarised in Table 2. The structure factors and
coordinates for T-stateMtbPYK,MtbPYK-OX,MtbPYK-OX/ATP/AMP,MtbPYK-
OX/G6P, MtbPYK-OX/AMP/G6P and MtbPYK-OX/AMP/G6P (soak) have been
deposited in the RCSB Protein Data Bank as PDB entries 5WRP, 5WS8, 5WS9,
5WSA, 5WSB and 5WSC, respectively.
Structure analysis. The program Superpose40 in the CCP441 suite was used to
calculate the allosteric rigid-body rotations from the superposition of T-state and
R-state tetramers as described previously26. Both RMS differences and rotation
matrices were calculated in the superposition process26.
The equivalent Cα atom distances of superposed structures are analysed by
heat-map analysis to highlight the conformational changes within structures. AC-
cores (A and C domains, residues 1–70 and 168–472) from each R-state MtbPYK
structure were superposed (Cα superposition) onto the AC-core of the T-state
structure using program Superpose40. Values of equivalent Cα distances (Dist.)
from each pair of superposition were used to generate heat maps by GraphPad
Prism 7. The increase of distance is represented as a blue to red gradient.
Molecular simulations and structural network analysis. Three MtbPYK crystal
structures with OX/G6P, OX/AMP, OX/AMP/G6P bound, were prepared using
Visual Molecular Dynamics (VMD)42. Each tetrameric structure was solvated in a
sufﬁciently large water box with salinity set to 150 mM NaCl. The systems, typically
involving 220,000 atoms, were then subjected to all-atom MD simulations for 2 ns
with positional restraints to the backbone atoms and a further 150 ns without any
restraints. The simulations were performed using NAMD 2.1043 assuming the
CHARMM36 force ﬁeld for the protein44 and assuming the TIP3P model for water
molecules45. The CHARMM parameters for oxalate, AMP and G6P were obtained
from cgenff46, 47. Network analysis was performed to investigate the dynamic
coupling between oxalate and AMP/G6P. We calculated 1000 highly correlated
paths of residues between ligand sites of interest for every MtbPYK monomer by
employing the weighted implementation of suboptimal paths (WISP) algorithm28,
48. Therefore, a total of 4000 suboptimal paths were collected for the MtbPYK
tetramer. To perform community network analysis49, a weighted network was ﬁrst
constructed where each residue represents a node and the weight of the connection
between nodes represents their respective correlation values. Communities were
then identiﬁed such that each community contains a group of highly correlated
residues50. Note that the simulation has converged after 20 ns (Supplementary
Fig. 10) and all analyses were done on the last 100 ns of the MD simulation
trajectory with 20 ps interval.
Mycobacterium bovis BCG culture and nutrient starvation. Isogenic freezer
stocks of Mycobacterium bovis bacille Calmette Guérin (BCG) Pasteur strain
1172P2 were used for starter cultures in 50 ml conical tubes, which were subse-
quently passaged into roller bottles with supplemented 7H9 medium51. To obtain
nutrient-deprived cultures, BCG were grown to OD600 of 0.8–1.0 and washed twice
in PBS (pH 7.4) containing 137 mM NaCl, 2.7 mM KCl, 10 mM NaH2PO4, 1.8 mM
KH2PO4, then re-suspended in PBS with 0.05% Tyloxapol to an OD600 of ~1.0 in
roller bottles for up to 22 days. At 4, 10 and 22 d post-nutrient deprivation (termed
S4, S10 and S22, respectively), samples from 4 independent cultures were taken for
metabolic assessment. The remaining samples at S22 were re-inoculated into
nutrient replete 7H9 at a starting OD600 of 0.1. The metabolites in these cultures
(termed R6) are assessed 6 d post inoculation. CFUs for BCG were determined
from 10-fold serial dilution plating on 7H10 agar at 37 °C for 3 w.
Metabolite extraction and targeted metabolomics. Metabolite extraction fol-
lowed the published report52. Brieﬂy, cell cultures were harvested at given time
points, rapidly quenched and spun down. Cell pellets were resuspended in acet-
onitrile:methanol:water (2:2:1) and lysed mechanically with 0.1-mm silica beads by
using Qiagen TissuelyserII. The lysates were collected and evaporated to dryness in
a vacuum evaporator, and the dry extracts were redissolved in 100 µl of 98:2 water/
methanol for liquid chromatography-mass spectrometry (LC-MS) analysis.
The targeted LC-MS/MS analysis was performed with Agilent 1290 ultrahigh
pressure liquid chromatography system coupled to a 6460 Triple Quadrupole mass
spectrometer equipped with a dual-spray electrospray ionization source with Jet
StreamTM (Agilent Technologies, Santa Clara, CA). Chromatographic separation
was achieved by using Phenomenex (Torrance, CA) RezexTM ROA-Organic Acid
H + (8%) column (2.1 × 100 mm, 3 µm) and the compounds were eluted at
40 °C with an isocratic ﬂow rate of 0.3 ml min−1 of 0.1% formic acid in water. The
auto-sampler was cooled at 4 °C and an injection volume of 5 μl was used.
Electrospray ionisation was performed in negative ion mode with the following
source parameters: drying gas temperature 300 °C with a ﬂow of 10 l min−1,
nebulizer gas pressure 40 psi, sheath gas temperature 350 °C with a ﬂow of
11 l min−1, capillary voltage 3000 V and nozzle voltage 500 V. Compounds were
quantiﬁed in multiple reaction monitoring (MRM) mode with the following
transitions: m/z 426> 124 and m/z 426> 79 for adenosine diphosphate (ADP),
m/z 259> 199 and m/z 259> 138.9 for glucose 6-phosphate (G6P), m/z 87> 43.1
and m/z 87> 32.1 for pyruvate, m/z 167> 79 and m/z 167> 63 for
phosphoenolpyruvic acid (PEP), m/z 229> 169.1 and m/z 229> 138.9 for ribose
5-phosphate (R6P), m/z 339> 96.9 and m/z 339> 79 for fructose 1,6-bisphosphate
(F16BP). Adenosine monophosphate (AMP) was analysed using Agilent 1290
ultrahigh pressure liquid chromatography system equipped with a 6520 QTOF
mass spectrometer equipped with a dual-spray electrospray ionization source
(Agilent Technologies, Santa Clara, CA). The column used for the separation was
an Agilent rapid resolution HT Zorbax SB-C18 (2.1×100 mm, 1.8 mm). The oven
temperature was set at 45 °C and the ﬂow rate was set at 0.4 ml min−1. The gradient
mobile phase consisted of 0.1% formic acid in water (A) and 0.1% formic acid in
methanol (B). Metabolites were eluted with the following gradient: 0 to 7 min,
2–70% B; 7 to 8 min, 70–100% B; 8–11 min, hold at 100% B, 11–11.1 min, 100-2%
B. The auto-sampler was cooled at 4 °C and a 5 μl injection volume was used. Mass
spectrometry was performed at positive ion electrospray ionization mode and the
mass data were collected between m/z 100 and 600 Da at a scan rate of 2 spectra
per second. The ion spray voltage and the heated capillary temperature was set at
4000 V and 350 °C, respectively The drying gas and nebulizer nitrogen gas ﬂow
rates were set to 12.0 l min−1 and 50 psi, respectively. Two reference masses were
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continuously infused to the system to ensure mass accuracy during the run: m/z
121.0509 (C5H4N4) and m/z 922.0098 (C18H18O6N3P3F24). The MassHunter
software (Agilent Technologies, USA) was used to collect and process the data.
Residual protein content was determined to normalise samples to cell biomass
(BCA protein assay kit; Thermo Scientiﬁc). The metabolic abundance data were
normalised to protein concentration.
Data availability. Coordinates and structure factors for the T-state structure
MtbPYK, R-state complexes MtbPYK-OX, MtbPYK-OX/AMP/ATP, MtbPYK-OX/
G6P, MtbPYK-OX/AMP/G6P,MtbPYK-OX/AMP/G6P (soaking method) have been
deposited in the Protein Data Bank under accession codes 5WRP, 5WS8, 5WS9,
5WSA, 5WSB and 5WSC, respectively. The authors declare that the data supporting
the ﬁndings of this study are available within the article and its Supplementary
Information Files, or from the corresponding authors upon reasonable request.
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